Sydney, Australia (PRWEB) July 19, 2012
SomnoMed announced today that its 100,000th device was delivered in June.
“This is a remarkable milestone for SomnoMed,” said Dr. Peter Neustadt, Executive Chairman of SomnoMed Limited. “Not only does this demonstrate our company’s global leadership in the oral appliance therapy market but it underlines the quality, effectiveness and safety of our SomnoDent® products.”
“With over 100,000 patients in treatment, since the start of our company in 2004, we can state that SomnoDent® is not only the most clinically researched and medically approved MAS device in the world, but it is also arguably the safest, in the absence of any threatened or actual legal action against us. There is now no impediment to work closely together with medical specialists to increase the acceptance of oral appliance therapy as a first line treatment for all mild and moderate conditioned patients and for the majority of diagnosed patients who are rejecting CPAP treatment.”
The 100,000th patient suffered from Moderate Obstructive Sleep Apnea with an AHI of 15. When asked why the SomnoDent sleep apnea appliance was chosen for this patient, the qualified and experienced dentist said, “She had excellent dentition and a minimal jaw opening, which meant we needed to use a thin, comfortable appliance without restriction in movement. She tended to have some concerns regarding comfort and limited opening.” The patient was provided treatment options such as CPAP therapy and oral appliance therapy, and chose the SomnoDent.
SomnoMed recently announced changes in its top management structure and a significant expansion of its medical capabilities in the US, which will include the addition of a Chief Medical Officer, the formation of a Medical Advisory Board and the addition of several staff in the marketing and sales area with a medical background.
“After building the foundation of our global business in the last five years we are now entering the next stage in the development of our business, which will see SomnoMed establishing itself in the mainstream of the medical device industry treating patients with Sleep related-Breathing Disorders. Our rate of growth has been very impressive over the last five years and we believe that these developments will allow us to substantially increase our growth over the next five years,” said Dr.Neustadt.
Dr. Peter Neustadt
Chairman, SomnoMed Limited
Ph +61 2 9467 0400 or +61 (0) 414 566 592-m
SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 100,000 patients in 22 countries.